Endocyte weakness a buying opportunity, says Brean Capital

November 6, 2013

Brean Capital believes the recent weakness in Endocyte in the wake of positive developments in its TARGET NSCLC Trial and ahead of EU approval are overblown. The firm believes investors should buy into the weakness ahead of its approval as well as its expanding pipeline. Shares are Buy rated with a $21 price target.